Target PharmaSolutions has announced a strategic partnership with Bristol-Myers Squibb to conduct a longitudinal observational study that will evaluate patients with inflammatory bowel disease, including adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate colitis, according to a company press release.
“TARGET-IBD continues to collect valuable real-world data which enhances our understanding of the natural history of inflammatory bowel disease and the impact of different treatment paradigms on patient populations over time,” Millie D. Long, MD, MPH, associate professor of medicine in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, said in the release. “The outcomes from real-world evidence can help doctors as they work to provide treatments to individual patients in real-life settings. This is particularly important given the ongoing innovation in the treatment of inflammatory bowel disease.”
TARGET-IBD currently has more than 1,850 patients across 30 investigative sites. The trial is led by an academic steering committee co-chaired by Long, Bruce E. Sands, MD, MS, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and David T. Rubin, MD, AGAF, co-director of the Digestive Diseases Center at the University of Chicago Medicine.
The trial’s design, according to the release, is disease focused, not treatment-specific, which allows for continuous acquisition of natural history and outcomes data, including patient reported outcomes, as new treatments continue to enter the market and clinical programs evolve.
“TARGET-IBD continues to make tremendous progress by enrolling a diverse patient cohort – including adult and pediatric patients – from a network of academic and community sites,” Meg Powell, PharmD, CEO of Target PharmaSolutions, said in the release. “The meticulously detailed real-world data it is collecting from these patients, such as severity of disease, is valuable for TARGET-IBD industry partners like BMS as they work to develop treatments to enhance patient outcomes. Our partnership demonstrates a shared vision of advancing IBD research and builds on our current partnership with Bristol-Myers Squibb for TARGET-NASH and TARGET-HCC.”